Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bayer AG has announced a new observational study titled ‘Retrospective, Non-interventional Database Study for the Evaluation of Real-world Drug Use Patterns, Clinical Characteristics and Clinical Outcomes in Patients Initiated on Vericiguat in India.’ The study aims to evaluate the safety and efficacy of Vericiguat, a drug prescribed for chronic heart failure with reduced ejection fraction (HFrEF) in Indian patients. The study is significant as it seeks to provide real-world data on Vericiguat’s use, which is currently limited.
The intervention being tested is Vericiguat, a drug that enhances the activity of soluble guanylate cyclase (sGC) to relax blood vessels and improve heart function. It is already approved for use in India for patients with worsening chronic HFrEF.
This study is designed as an observational cohort study with a retrospective time perspective. It will collect data from existing medical records without requiring additional tests or visits, focusing on real-world treatment patterns and outcomes.
The study is set to start on August 1, 2025, with an estimated completion date yet to be announced. The last update was submitted on August 5, 2025. These dates are crucial for investors to track the study’s progress and potential market impact.
The market implications of this study could be significant for Bayer AG, as positive results may enhance Vericiguat’s market position and boost investor confidence. In the competitive landscape of heart failure treatments, real-world evidence could differentiate Vericiguat from other therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.